回调或由获利了结导致 10月8日，港股早盘低开。Wind数据显示，截至收盘，恒生指数下跌0.48%，报26829.46点。同期，恒 生科技指数下跌0.55%，报6514.19点。 10月8日，国庆假期最后一天，港股遭遇回调。具体来看，截至收盘，恒生指数、恒生科技指数双双下 跌0.48%、0.55%。若拉长时间至10月以来，港股市场则呈现先扬后抑态势，恒生指数突破年内新高后 连续回调。回顾年内，在港股走势表现亮眼的背景下，多只港股主题基金业绩突出，最高已赚155%。 有业内人士指出，未来港股仍有向上空间，科技板块仍将是市场关注的焦点，板块或呈现"波动上行、 龙头领跑"的格局。港股主题基金未来仍具备较好的投资机会，特别是聚焦新经济、科技和创新产业的 基金。 值得关注的是，在港股细分板块中，创新药行情的"狂飙"备受关注。仅从市场多只指数基金跟踪的中证 港股通创新药指数来看，据中证指数官网，截至9月30日，该指数年内涨幅已达118.52%。 这一背景下，多家公募旗下的港股创新药ETF或相关被动指数基金的前三季度收益也均翻倍，包括万家 中证港股通创新药ETF、景顺长城中证港股通创新药ETF、中欧中证港股通创新药指数A/ ...

回调或由获利了结导致 10月8日，国庆假期最后一天，港股遭遇回调。具体来看，截至收盘，恒生指数、恒生科技指数双双下跌0.48%、0.55%。若 拉长时间至10月以来，港股市场则呈现先扬后抑态势，恒生指数突破年内新高后连续回调。回顾年内，在港股走势表现亮 眼的背景下，多只港股主题基金业绩突出，最高已赚155%。有业内人士指出，未来港股仍有向上空间，科技板块仍将是市 场关注的焦点，板块或呈现"波动上行、龙头领跑"的格局。港股主题基金未来仍具备较好的投资机会，特别是聚焦新经济、 科技和创新产业的基金。 就具体产品看，截至9月末，汇添富香港优势精选混合C类份额和A类份额的前三季度收益率分别达155.14%和155.09%，排 名全市场基金收益第三、四名。同期，中银港股通医药混合发起A/C的收益率也达126.55%、125.48%，排名居前。 值得关注的是，在港股细分板块中，创新药行情的"狂飙"备受关注。仅从市场多只指数基金跟踪的中证港股通创新药指数来 看，据中证指数官网，截至9月30日，该指数年内涨幅已达118.52%。 这一背景下，多家公募旗下的港股创新药ETF或相关被动指数基金的前三季度收益也均翻倍，包括万家中证 ...

本文共1900 字 阅读完约7分钟 金融投资报记者 刘庆华 三季度行情即将收官。在经历了一季度的震荡上行，一季度末和二季度初的调整之后，A股市场和港股 市场自4月中旬以来持续走高，并在三季度迭创阶段新高，投向股票资产的基金也获得了不错的收益。 Wind数据显示，今年以来截至9月26日，在权益类基金和QDII基金中，合计共有37只基金收益率翻倍。 主动管理的A股权益类基金中，重仓AI的基金收益率领先，单只基金收益率最高接近190%。被动指数 型基金中，跟踪创新药、通信、人工智能等方向的基金收益率居前。 01 主动权益基金：31只基金收益翻倍 投向A股的主动权益类基金今年以来表现不俗，超额回报出色。截至9月26日，算术平均收益率为 30.32%（剔除年内成立的基金），超过98%的主动权益类基金取得正收益，收益率超50%的基金达到 684只，占比超15%。其中，收益率超过100%的基金有31只，单只基金最高收益率接近190%。 永赢科技智选A以189.58%的收益率领跑。二季度以来该基金净值涨幅明显，近半年的收益率超过了 164%。从基金季报可以看到，二季度末该基金有明显的调仓动作，前十大重仓股全部更换，将持仓重 ...

Core Viewpoint - The A-share market has shown significant strength in the first eight months of the year, leading to a strong performance of public equity funds, with many funds achieving over 100% returns [2][6][13]. Group 1: Market Performance - The main indices have experienced substantial gains, with the North Exchange 50 index rising by 51.49%, and several other indices, including the Sci-Tech Innovation 50 and the ChiNext index, increasing by over 30% [2][4]. - In August, the Shanghai Composite Index broke through the 3,800-point mark, reaching a 10-year high, with the Sci-Tech series indices showing strong performance, with increases of 32.25% and 28.00% respectively [4]. Group 2: Fund Performance - The average net value growth rate of active equity funds in the first eight months reached 23.83%, with the best-performing fund achieving a growth rate exceeding 175% [6][10][11]. - A total of 603 active equity funds have recorded a net value growth rate exceeding 50%, with 21 funds surpassing 100% [13][20]. - The average net value growth rates for ordinary stock funds and mixed equity funds were 28.38% and 28.79% respectively, indicating strong recovery in net values [9]. Group 3: Sector Opportunities - Structural opportunities have emerged in sectors such as the North Exchange, innovative pharmaceuticals, humanoid robots, AI, and semiconductors, contributing to the strong performance of funds managed by adept fund managers [12][20]. - The innovative pharmaceutical sector has been a standout performer, with the Hong Kong Stock Connect innovative pharmaceutical index showing a cumulative annual increase of 108.24% [24]. Group 4: Future Outlook - If the current market trends continue, 2025 is expected to be a breakout year for active equity fund performance [21]. - The market is experiencing a rebalancing of underlying funds, with indications of capital flowing from dollar assets to non-dollar assets, and from the bond market to the equity market [26].

Group 1 - The innovative drug sector has been actively rising since the end of July, with significant increases in various sub-concept indices [1] - A substantial amount of capital has flowed into the innovative drug field through ETFs, with a total net inflow of 7.551 billion yuan in August [1] - 24 innovative drug ETFs, including QDII, have recorded gains in August, with nearly 80% of them experiencing net inflows [1] Group 2 - The Huatai-PineBridge Hong Kong Innovative Drug ETF saw a net inflow of 2.829 billion yuan in August, leading the sector [1] - The GF CSI Hong Kong Innovative Drug ETF followed closely with a net inflow of 2.711 billion yuan [1] - Other ETFs such as the Hong Kong Innovative Drug ETF, Invesco Great Wall CSI Hong Kong Innovative Drug ETF, and GF Innovative Drug ETF also reported significant net inflows [1]

Group 1 - The A-share market indices have recently reached new highs, leading to increased attention on ETFs, with trading volumes exceeding 400 billion yuan on several days [1] - The overall ETF market saw significant trading activity, with daily trading volumes of 410.5 billion yuan, 435.1 billion yuan, and nearly 493 billion yuan over three consecutive days [1] - A total of 15 broad-based ETFs had average daily trading volumes exceeding 1 billion yuan during this period, with notable performances from specific ETFs like Huaxia's STAR Market 50 ETF and the CSI A500 ETF [1] Group 2 - The average return of funds this year is 10.44%, while ETFs have performed better with an average return of 15.51%, with several ETFs exceeding 100% returns [2] - Analysts suggest a "core-satellite" strategy for asset allocation, where broad-based index funds serve as the main investment, while specific industry index funds are allocated as satellite positions [2] - The growth of stock ETFs contrasts with active equity funds, highlighting the diverse applications of ETFs in asset allocation and strategy [3]

Group 1 - As of July 31, 12 public funds have achieved a net value growth rate exceeding 100% in 2023, primarily focusing on themes such as innovative drugs, biomedicine, and healthcare, closely linked to the strong performance of the Hong Kong innovative drug sector [1][2] - The top-performing fund, Huatai-PB Hong Kong Advantage Selection A, boasts a 143.24% year-to-date net value growth rate, heavily invested in Hong Kong innovative drugs, with its top ten holdings all being Hong Kong innovative drug stocks [2][3] - Other notable funds with over 100% growth include Changcheng Medical Industry Selection A and Bank of China Hong Kong Stock Connect Medical A, along with several ETFs focused on innovative drugs [2][3] Group 2 - The strong performance of the Hong Kong innovative drug sector is driven by three main factors: increased collaboration needs due to multinational pharmaceutical companies facing "patent cliffs," many biotech companies approaching breakeven within three to five years, and comprehensive policy support from research to payment [3] - The manager of Huatai-PB Hong Kong Stock Connect Innovative Drug ETF noted a significant acceleration in Chinese innovative drug companies' overseas expansion since 2025, with multiple large overseas licensing deals indicating global recognition of China's innovation capabilities [3] - The manager of Huatai-PB Hong Kong Advantage Selection Mixed Fund emphasized that with the recovery of market risk appetite, innovative drug companies with core competitiveness will demonstrate long-term growth value, focusing on globally competitive innovative drug firms and high-quality medical device leaders [3] Group 3 - The Hong Kong stock market has seen significant liquidity improvement and increased trading activity in 2023, enhancing its resilience and attracting global capital to quality assets [4] - The Hang Seng Index has outperformed major global markets with over a 20% increase in the first half of the year, and net inflows from southbound funds exceeded 700 billion yuan, marking a record high [4] - Looking ahead, the Hong Kong market is expected to continue its diversification trend, supported by improving free cash flow and increasing share buybacks among listed companies, which may lay a solid foundation for long-term stable performance [4]

Group 1 - As of July 31, 12 public funds have achieved a net value growth rate exceeding 100% in 2023, primarily focusing on themes such as innovative drugs, biomedicine, and healthcare, closely linked to the strong performance of the Hong Kong innovative drug sector [1][2] - The top-performing fund, Huatai-PB Hong Kong Advantage Selection A, has a net value growth rate of 143.24%, heavily invested in Hong Kong innovative drugs, with its top ten holdings all being Hong Kong innovative drug stocks [2][3] - Other funds, including Changcheng Medical Industry Selection A and Bank of China Hong Kong Stock Connect Medicine A, also reported net value growth rates over 100%, indicating a robust performance across various funds in the innovative drug sector [2][3] Group 2 - The strong performance of the Hong Kong innovative drug sector is driven by three main factors: increased collaboration demand due to multinational pharmaceutical companies facing "patent cliffs," many biotech companies approaching breakeven within three to five years, and comprehensive policy support from R&D to payment [3] - The manager of Huatai-PB Hong Kong Stock Connect Innovative Drug ETF noted a significant acceleration in Chinese innovative drug companies' overseas expansion since 2025, with multiple large overseas licensing deals indicating global recognition of China's innovation capabilities [3] - The manager of Huatai-PB Hong Kong Advantage Selection Mixed Fund emphasized that with the recovery of market risk appetite, innovative drug companies with core competitiveness will demonstrate long-term growth value, focusing on globally competitive innovative drug firms and high-quality medical device leaders [3] Group 3 - The Hong Kong stock market has seen significant liquidity improvement and increased trading activity, enhancing its resilience and overall performance, with the Hang Seng Index rising over 20% this year, outperforming major global markets [4] - The net inflow of over 700 billion yuan from southbound funds has set a new high for the same period, indicating a strong demand for quality assets in the Hong Kong market [4] - Looking ahead, the Hong Kong market is expected to continue its diversification trend, supported by ongoing policy measures, improved free cash flow among listed companies, and an increasing buyback scale, which reflects enhanced corporate quality and shareholder return awareness [4][5]

Group 1 - Several securities firms, including CITIC Securities and Guosen Securities, have quickly launched trading permissions for the new Sci-Tech Growth Board, indicating high market interest in this new segment [1] - Investors need to meet a threshold of 500,000 yuan in assets and have two years of investment experience to participate, which helps filter qualified investors and manage risks [1] - The introduction of the Sci-Tech Growth Board enhances the multi-tiered capital market structure, providing financing channels for tech innovation companies, which is expected to boost overall market vitality and innovation momentum in the long term [1] Group 2 - On July 29, Founder Securities announced that its major shareholder, China Cinda Asset Management, did not execute its planned share reduction, which is seen as a positive signal for the company's long-term value [2] - The unchanged shareholding of China Cinda, which holds 593 million shares (7.2% of total shares), may help stabilize market sentiment and alleviate investor concerns about share dilution [2] - This situation is likely to support the brokerage sector and enhance confidence in financial stocks, contributing to market stability [2] Group 3 - In July, over 900 billion yuan worth of new funds were issued, indicating a recovery in market confidence [3] - The increase in stock and bond fund shares, driven by the equity market and innovative products like the Sci-Tech Bond ETF, reflects a growing risk appetite among investors [3] - The decline in mixed fund shares suggests a preference for clearer directional investments, which may lead to increased activity in related sectors and improved market liquidity [3] Group 4 - Seven ETFs have achieved "doubling" performance this year, with the top performer, Huatai-PB Hang Seng Innovation Drug ETF, showing a 107.67% return [4] - The strong performance of Hong Kong innovation drug ETFs highlights the robust market interest in the innovative drug sector, potentially attracting more capital into the healthcare segment [4] - Continued advancements in innovative drug research and supportive policies are key drivers for the pharmaceutical industry, with high-performing ETFs likely to enhance investor risk appetite [4]

Core Insights - Seven ETFs have achieved "doubling" performance in net value returns this year, indicating a strong market trend in the ETF sector [1] Group 1: ETF Performance - As of July 29, 2023, seven non-cash ETFs have seen their net value returns double this year [1] - The leading performer is the Huatai-PB Hang Seng Innovative Drug ETF, with a year-to-date net value return of 107.67% [1] - The second-best performer is the Wanji Zhongzheng Hong Kong Innovative Drug ETF, achieving a net value return of 106.87% [1] - The third position is held by the GF Zhongzheng Hong Kong Innovative Drug ETF, with a net value return of 106.39% [1] - Other notable ETFs with doubled net value returns include the Huatai-PB Hang Seng Innovative Drug ETF (106.36%), Yinhua Guozheng Hong Kong Innovative Drug ETF (105.67%), and others, with returns ranging from 101.21% to 106.36% [1]